Cover Image
Market Research Report

Europe Cancer Immunotherapy Market (2018 - 2024)

Published by KBV Research Product code 763725
Published Content info 86 Pages
Delivery time: 1-2 business days
Price
Back to Top
Europe Cancer Immunotherapy Market (2018 - 2024)
Published: December 20, 2018 Content info: 86 Pages
Description

The Europe Cancer Immunotherapy Market would witness market growth of 13.5 % CAGR during the forecast period (2018 - 2024). Cancer immunotherapy is the type of cancer treatment helping the immune system fight cancer. There are various kinds of cancer immunotherapies used and they are monoclonal antibody, therapeutic cancer vaccines, checkpoint inhibitors, cytokines, and others. Growing patient population that is suffering from different types of cancer such as lung cancer, breast cancer, ovarian cancer, and other cancers are the factors that drive the global cancer immunotherapy market. Additionally, growing geriatric population and governmental contribution to healthcare expenditure are some other factors that add to the market growth.

Based on technology, the market is segmented into Monoclonal Antibodies, Cytokines & Immunomodulators and other technology. Based on application, the market is segmented into Lung cancer, Breast cancer, Colorectal, Prostate cancer, Head & Neck cancer and other application. Based on end user the market is segmented into Hospitals, Clinics and other end user. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche Ltd

Table of Contents

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Europe Cancer Immunotherapy Market, by Technology
    • 1.4.2 Europe Cancer Immunotherapy Market, by Application
    • 1.4.3 Europe Cancer Immunotherapy Market, by End User
    • 1.4.4 Europe Cancer Immunotherapy Market, by Countries
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Europe Cancer Immunotherapy Market by Technology

    • 3.1.1 Europe Monoclonal Antibodies Cancer Immunotherapy Market by Country
    • 3.1.2 Europe Cytokines & Immunomodulators Cancer Immunotherapy Market by Country
    • 3.1.3 Europe Other Technology Cancer Immunotherapy Market by Country

Chapter 4. Europe Cancer Immunotherapy Market by Application

    • 4.1.1 Europe Cancer Immunotherapy Lung Cancer Market by Country
    • 4.1.2 Europe Cancer Immunotherapy Breast Cancer Market by Country
    • 4.1.3 Europe Cancer Immunotherapy Colorectal Cancer Market by Country
    • 4.1.4 Europe Cancer Immunotherapy Melanoma Market by Country
    • 4.1.5 Europe Cancer Immunotherapy Prostate Cancer Market by Country
    • 4.1.6 Europe Cancer Immunotherapy Head & Neck Cancer Market by Country
    • 4.1.7 Europe Other Application Cancer Immunotherapy Market by Country

Chapter 5. Europe Cancer Immunotherapy Market by End User

    • 5.1.1 Europe Hospitals Cancer Immunotherapy Market by Country
    • 5.1.2 Europe Clinics Cancer Immunotherapy Market by Country
    • 5.1.3 Europe Other End User Cancer Immunotherapy Market by Country

Chapter 6. Europe Cancer Immunotherapy Market by Country

  • 6.1 Germany Cancer Immunotherapy Market
    • 6.1.1 Germany Cancer Immunotherapy Market by Technology
    • 6.1.2 Germany Cancer Immunotherapy Market by Application
    • 6.1.3 Germany Cancer Immunotherapy Market by End User
  • 6.2 UK Cancer Immunotherapy Market
    • 6.2.1 UK Cancer Immunotherapy Market by Technology
    • 6.2.2 UK Cancer Immunotherapy Market by Application
    • 6.2.3 UK Cancer Immunotherapy Market by End User
  • 6.3 France Cancer Immunotherapy Market
    • 6.3.1 France Cancer Immunotherapy Market by Technology
    • 6.3.2 France Cancer Immunotherapy Market by Application
    • 6.3.3 France Cancer Immunotherapy Market by End User
  • 6.4 Russia Cancer Immunotherapy Market
    • 6.4.1 Russia Cancer Immunotherapy Market by Technology
    • 6.4.2 Russia Cancer Immunotherapy Market by Application
    • 6.4.3 Russia Cancer Immunotherapy Market by End User
  • 6.5 Spain Cancer Immunotherapy Market
    • 6.5.1 Spain Cancer Immunotherapy Market by Technology
    • 6.5.2 Spain Cancer Immunotherapy Market by Application
    • 6.5.3 Spain Cancer Immunotherapy Market by End User
  • 6.6 Italy Cancer Immunotherapy Market
    • 6.6.1 Italy Cancer Immunotherapy Market by Technology
    • 6.6.2 Italy Cancer Immunotherapy Market by Application
    • 6.6.3 Italy Cancer Immunotherapy Market by End User
  • 6.7 Rest of Europe Cancer Immunotherapy Market
    • 6.7.1 Rest of Europe Cancer Immunotherapy Market by Technology
    • 6.7.2 Rest of Europe Cancer Immunotherapy Market by Application
    • 6.7.3 Rest of Europe Cancer Immunotherapy Market by End User

Chapter 7. Company Profiles

  • 7.1 Amgen Inc.
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Segmental & Regional Analysis
    • 7.1.4 Research and Development Expense
  • 7.2 Merck & Company, Inc.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Regional and Segmental Analysis
    • 7.2.4 Research & Development
  • 7.3 Pfizer Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental &Regional Analysis
    • 7.3.4 Revenue analysis by Region
    • 7.3.5 Research and Development
  • 7.4 Immunomedics Inc.
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Revenue Analysis by Region
    • 7.4.4 Research and Development
  • 7.5 Astrazeneca Plc.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Segmental analysis
    • 7.5.4 Research & Development
  • 7.6 F. Hoffmann-La Roche Ltd.
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Revenue & Segment analysis
    • 7.6.4 Research and Development
  • 7.7 Eli Lilly and Company
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Segmental and Regional Analysis
    • 7.7.4 Research & Development Expense
  • 7.8 Novartis AG
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expense
  • 7.9 Bristol-Myers Squibb Company
    • 7.9.1 Company Overview
  • 7.1 Bayer AG
    • 7.10.1 Company Overview
    • 7.10.2 Financial Analysis
    • 7.10.3 Segmental and Regional Analysis
    • 7.10.4 Research & Development Expense

LIST OF TABLES

  • TABLE 1 EUROPE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 2 EUROPE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 3 EUROPE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 4 EUROPE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 5 EUROPE MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 6 EUROPE MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 7 EUROPE CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 8 EUROPE CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 9 EUROPE OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 10 EUROPE OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 11 EUROPE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 12 EUROPE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 13 EUROPE CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 14 EUROPE CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 15 EUROPE CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 16 EUROPE CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 17 EUROPE CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 18 EUROPE CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 19 EUROPE CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 20 EUROPE CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 21 EUROPE CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 22 EUROPE CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 23 EUROPE CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 24 EUROPE CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 25 EUROPE OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 26 EUROPE OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 27 EUROPE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 28 EUROPE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 29 EUROPE HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 30 EUROPE HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 31 EUROPE CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 32 EUROPE CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 33 EUROPE OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 34 EUROPE OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 35 EUROPE CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 36 EUROPE CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 37 GERMANY CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 38 GERMANY CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 39 GERMANY CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 40 GERMANY CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 41 GERMANY CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 42 GERMANY CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 43 GERMANY CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 44 GERMANY CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 45 UK CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 46 UK CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 47 UK CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 48 UK CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 49 UK CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 50 UK CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 51 UK CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 52 UK CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 53 FRANCE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 54 FRANCE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 55 FRANCE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 56 FRANCE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 57 FRANCE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 58 FRANCE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 59 FRANCE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 60 FRANCE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 61 RUSSIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 62 RUSSIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 63 RUSSIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 64 RUSSIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 65 RUSSIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 66 RUSSIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 67 RUSSIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 68 RUSSIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 69 SPAIN CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 70 SPAIN CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 71 SPAIN CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 72 SPAIN CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 73 SPAIN CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 74 SPAIN CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 75 SPAIN CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 76 SPAIN CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 77 ITALY CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 78 ITALY CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 79 ITALY CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 80 ITALY CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 81 ITALY CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 82 ITALY CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 83 ITALY CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 84 ITALY CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 85 REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 86 REST OF EUROPE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 87 REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 88 REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 89 REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 90 REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 91 REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 92 REST OF EUROPE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 93 KEY INFORMATION-AMGEN INC.
  • TABLE 94 KEY INFORMATION-MERCK & COMPANY INC.
  • TABLE 95 KEY INFORMATION- PFIZER INC.
  • TABLE 96 KEY INFORMATION- IMMUNOMEDICS INC.
  • TABLE 97 KEY INFORMATION- ASTRAZENECA PLC.
  • TABLE 98 KEY INFORMATION- F. HOFFMANN-LA ROCHE LTD.
  • TABLE 99 KEY INFORMATION - ELI LILLY AND COMPANY
  • TABLE 100 KEY INFORMATION - NOVARTIS AG
  • TABLE 101 KEY INFORMATION - BRISTOL-MYERS SQUIBB COMPANY
  • TABLE 102 KEY INFORMATION - BAYER AG
Back to Top